Literature DB >> 19609727

Younger age-at-diagnosis for familial malignant testicular germ cell tumor.

Phuong L Mai1, Bingshu E Chen, Kathy Tucker, Michael Friedlander, Kelly-Anne Phillips, David Hogg, Michael A S Jewett, Istvan Bodrogi, Lajos Geczi, Edith Olah, Ketil Heimdal, Sophie D Fosså, Katherine L Nathanson, Larissa Korde, Douglas F Easton, Darshna Dudakia, Robert Huddart, Michael R Stratton, D Timothy Bishop, Elizabeth A Rapley, Mark H Greene.   

Abstract

One of the clinical hallmarks of hereditary cancer susceptibility disorders is a younger-than-usual age at diagnosis. Familial aggregation of testicular germ cell tumor (TGCT) has been reported, but data on whether familial TGCT cases are diagnosed at an earlier age are inconclusive. Here we compared the age at diagnosis of familial TGCT cases with that of population cases in several countries. Familial TGCT is defined as affected individuals from families with >or=2 cases of TGCT. Age at diagnosis of familial cases from the United States, Canada, United Kingdom, Australia and New Zealand, Norway, and Hungary was compared to cases identified in population-based cancer registries from the respective country, using the generalized estimation equation method. Age at diagnosis was statistically significantly younger for familial TGCT cases from North America (P = 0.024), the United Kingdom (P < 0.0001), and Australia and New Zealand (P = 0.0033) compared with population cases. When stratified by histology, the difference in age at diagnosis distribution between familial and population cases was observed for seminoma cases from North America (P = 0.002) and the United Kingdom (P < 0.0001) and non-seminoma cases from the United Kingdom (P = 0.029) and Australia and New Zealand (P = 0.0023). In summary, we found that the age at diagnosis for familial TGCT cases is, on the average, 2-3 years younger than that for the population cases in North America, United Kingdom, and Australia and New Zealand. The younger age at diagnosis might be suggestive of a genetic basis for familial TGCT.

Entities:  

Mesh:

Year:  2009        PMID: 19609727      PMCID: PMC2903045          DOI: 10.1007/s10689-009-9264-6

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  17 in total

1.  Familial testicular cancer in a single-centre population.

Authors:  D J Sonneveld; D T Sleijfer; H Schrafford Koops; R H Sijmons; W T van der Graaf; W J Sluiter; H J Hoekstra
Journal:  Eur J Cancer       Date:  1999-09       Impact factor: 9.162

2.  Genome-wide linkage screen for testicular germ cell tumour susceptibility loci.

Authors:  Gillian P Crockford; Rachel Linger; Sarah Hockley; Darshna Dudakia; Lola Johnson; Robert Huddart; Kathy Tucker; Michael Friedlander; Kelly-Anne Phillips; David Hogg; Michael A S Jewett; Radka Lohynska; Gedske Daugaard; Stéphane Richard; Agnes Chompret; Catherine Bonaïti-Pellié; Axel Heidenreich; Peter Albers; Edith Olah; Lajos Geczi; Istvan Bodrogi; Wilma J Ormiston; Peter A Daly; Parry Guilford; Sophie D Fosså; Ketil Heimdal; Sergei A Tjulandin; Ludmila Liubchenko; Hans Stoll; Walter Weber; David Forman; Timothy Oliver; Lawrence Einhorn; Mary McMaster; Joan Kramer; Mark H Greene; Barbara L Weber; Katherine L Nathanson; Victoria Cortessis; Douglas F Easton; D Timothy Bishop; Michael R Stratton; Elizabeth A Rapley
Journal:  Hum Mol Genet       Date:  2006-01-11       Impact factor: 6.150

3.  Concise handbook of familial cancer susceptibility syndromes - second edition.

Authors:  Noralane M Lindor; Mary L McMaster; Carl J Lindor; Mark H Greene
Journal:  J Natl Cancer Inst Monogr       Date:  2008

4.  Hereditary cancer, oncogenes, and antioncogenes.

Authors:  A G Knudson
Journal:  Cancer Res       Date:  1985-04       Impact factor: 12.701

5.  Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men.

Authors:  Sophie D Fosså; Jinbo Chen; Sara J Schonfeld; Katherine A McGlynn; Mary L McMaster; Mitchell H Gail; Lois B Travis
Journal:  J Natl Cancer Inst       Date:  2005-07-20       Impact factor: 13.506

Review 6.  Cancer screening in the United States, 2008: a review of current American Cancer Society guidelines and cancer screening issues.

Authors:  Robert A Smith; Vilma Cokkinides; Otis Webb Brawley
Journal:  CA Cancer J Clin       Date:  2008-04-28       Impact factor: 508.702

7.  Localisation of susceptibility genes for familial testicular germ cell tumour.

Authors:  Elizabeth A Rapley; Gillian P Crockford; Douglas F Easton; Michael R Stratton; D Timothy Bishop
Journal:  APMIS       Date:  2003-01       Impact factor: 3.205

8.  Familial risks for cancer as the basis for evidence-based clinical referral and counseling.

Authors:  Kari Hemminki; Jan Sundquist; Justo Lorenzo Bermejo
Journal:  Oncologist       Date:  2008-03

9.  Testis cancer.

Authors:  Mitchell H Sokoloff; Geoffrey F Joyce; Matthew Wise
Journal:  J Urol       Date:  2007-06       Impact factor: 7.450

10.  The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred.

Authors:  Phuong L Mai; Michael Friedlander; Kathy Tucker; Kelly-Anne Phillips; David Hogg; Michael A S Jewett; Radka Lohynska; Gedske Daugaard; Stéphane Richard; Catherine Bonaïti-Pellié; Axel Heidenreich; Peter Albers; Istvan Bodrogi; Lajos Geczi; Edith Olah; Peter A Daly; Parry Guilford; Sophie D Fosså; Ketil Heimdal; Ludmila Liubchenko; Sergei A Tjulandin; Hans Stoll; Walter Weber; Douglas F Easton; Darshna Dudakia; Robert Huddart; Michael R Stratton; Lawrence Einhorn; Larissa Korde; Katherine L Nathanson; D Timothy Bishop; Elizabeth A Rapley; Mark H Greene
Journal:  Urol Oncol       Date:  2009-01-22       Impact factor: 3.498

View more
  7 in total

1.  Testicular microlithiasis imaging and follow-up: guidelines of the ESUR scrotal imaging subcommittee.

Authors:  Jonathan Richenberg; Jane Belfield; Parvati Ramchandani; Laurence Rocher; Simon Freeman; Athina C Tsili; Faye Cuthbert; Michal Studniarek; Michele Bertolotto; Ahmet Tuncay Turgut; Vikram Dogra; Lorenzo E Derchi
Journal:  Eur Radiol       Date:  2014-10-15       Impact factor: 5.315

Review 2.  Familial testicular germ cell tumours.

Authors:  Christian P Kratz; Phuong L Mai; Mark H Greene
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2010-06       Impact factor: 4.690

Review 3.  Familial testicular germ cell tumors in adults: 2010 summary of genetic risk factors and clinical phenotype.

Authors:  Mark H Greene; Christian P Kratz; Phuong L Mai; Christine Mueller; June A Peters; Gennady Bratslavsky; Alex Ling; Peter M Choyke; Ahalya Premkumar; Janet Bracci; Rissah J Watkins; Mary Lou McMaster; Larissa A Korde
Journal:  Endocr Relat Cancer       Date:  2010-03-08       Impact factor: 5.678

4.  Prospectively Identified Incident Testicular Cancer Risk in a Familial Testicular Cancer Cohort.

Authors:  Anand Pathak; Charleen D Adams; Jennifer T Loud; Kathryn Nichols; Douglas R Stewart; Mark H Greene
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-08-11       Impact factor: 4.254

5.  Rare inactivating PDE11A variants associated with testicular germ cell tumors.

Authors:  Anand Pathak; Douglas R Stewart; Fabio R Faucz; Paraskevi Xekouki; Sara Bass; Aurelie Vogt; Xijun Zhang; Joseph Boland; Meredith Yeager; Jennifer T Loud; Katherine L Nathanson; Katherine A McGlynn; Constantine A Stratakis; Mark H Greene; Lisa Mirabello
Journal:  Endocr Relat Cancer       Date:  2015-12       Impact factor: 5.678

Review 6.  Etiology and early pathogenesis of malignant testicular germ cell tumors: towards possibilities for preinvasive diagnosis.

Authors:  Jenny E Elzinga-Tinke; Gert R Dohle; Leendert Hj Looijenga
Journal:  Asian J Androl       Date:  2015 May-Jun       Impact factor: 3.285

7.  Familial testicular germ cell tumor: no associated syndromic pattern identified.

Authors:  Christine M Mueller; Larissa A Korde; Mary L McMaster; June A Peters; Gennady Bratslavsky; Rissah J Watkins; Alex Ling; Christian P Kratz; Eric A Wulfsberg; Philip S Rosenberg; Mark H Greene
Journal:  Hered Cancer Clin Pract       Date:  2014-02-21       Impact factor: 2.857

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.